All In Biotech

Drug Trial Radar · NCT06154304

BE Study of Albuterol Sulfate Inhalation Aerosol 90 mcg Per Actuation in Patients With Stable Mild Asthma

To Compare the Bronchoprotective Effects of the Test and Reference Metered Dose Inhalers (MDIs) Containing Albuterol Sulfate Using Methacholine Bronchoprovocation Challenge Testing in Stable Mild Asthma Patients.

Last checked: Nov 20, 2026Latest source record: Jul 16, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 120 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

120

Actual

Start

Dec 6, 2023

Primary completion

Sep 16, 2024

Study completion Nov 29, 2024

Sponsor

Lead sponsor
Cipla Ltd.Industry
Sponsor type
Industry
First posted
Dec 4, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Crossover
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to demonstrate the pharmacodynamic bioequivalence of the test product to the reference product, using bronchoprovocation (methacholine challenge testing) in adult patients with stable mild asthma.

Conditions

  • Bronchial Asthma

Interventions

  • Albuterol Sulfate Inhalation Aerosol (90 mcg per actuation)Drug

    90 mcg

  • Ventolin HFA 90Mcg/Actuation Inhalation Aerosol_#1Drug

    90 mcg

  • Ventolin HFA, 90 Mcg/Inh Inhalation Aerosol_#2Drug

    180 mcg

  • PlaceboDrug

    Placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Provocative Dose of Methacholine Causing 20 % Fall (PD20) in FEV1(Forced Expiratory Volume in 1 second)Time frame: 1 day

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Velocity CLinical Research

    Medford, Oregon

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.